These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17041454)
1. Reactivation of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for acquired immunodeficiency syndrome. Drake WP; Byrd VM; Olsen NJ J Clin Rheumatol; 2003 Jun; 9(3):176-80. PubMed ID: 17041454 [TBL] [Abstract][Full Text] [Related]
2. Emergence of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for human immunodeficiency virus infection. Diri E; Lipsky PE; Berggren RE J Rheumatol; 2000 Nov; 27(11):2711-4. PubMed ID: 11093459 [TBL] [Abstract][Full Text] [Related]
3. Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Calza L; Manfredi R; Colangeli V; D'Antuono A; Passarini B; Chiodo F Int J STD AIDS; 2003 May; 14(5):356-9. PubMed ID: 12803945 [TBL] [Abstract][Full Text] [Related]
4. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients. Ho C; Lee S; Wong Kh; Cheng L; Lam M HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862 [TBL] [Abstract][Full Text] [Related]
5. [Systemic lupus erythematosus and HIV infection. A case report and review of the literature]. Calza L; Manfredi R; Colangeli V; Chiodo F Recenti Prog Med; 2002 Jan; 93(1):28-31. PubMed ID: 11850997 [TBL] [Abstract][Full Text] [Related]
6. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217 [TBL] [Abstract][Full Text] [Related]
7. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
8. An unusual multiplex systemic lupus erythematosus family with high prevalence of nephropathy, late-onset disease, and one member with disease-onset post-HIV therapy. Jakez-Ocampo J; Carrillo-Maravilla E; Richaud-Patin Y; Soto-Vega E; Atisha-Fregoso Y; Llorente L J Clin Rheumatol; 2008 Feb; 14(1):34-7. PubMed ID: 18431097 [TBL] [Abstract][Full Text] [Related]
9. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Moore RD; Keruly JC Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456 [TBL] [Abstract][Full Text] [Related]
10. Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence. Gaitan Cepeda LA; Ceballos Salobreña A; López Ortega K; Arzate Mora N; Jiménez Soriano Y Med Oral Patol Oral Cir Bucal; 2008 Feb; 13(2):E85-93. PubMed ID: 18223535 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy. Sheng WH; Hung CC; Wu RJ; Wang JT; Chen PJ; Chang SC; Kao JH Clin Infect Dis; 2007 Feb; 44(4):584-90. PubMed ID: 17243064 [TBL] [Abstract][Full Text] [Related]
12. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S; Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319 [TBL] [Abstract][Full Text] [Related]
13. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567 [TBL] [Abstract][Full Text] [Related]
14. Progressive supravenous granulomatous nodular eruption in a human immunodeficiency virus-positive intravenous drug user treated with highly active antiretroviral therapy. Fernández-Casado A; Martin-Ezquerra G; Yébenes M; Plana F; Elvira-Betanzos JJ; Herrero-González JE; Mariñoso ML; Pujol RM Br J Dermatol; 2008 Jan; 158(1):145-9. PubMed ID: 17941945 [TBL] [Abstract][Full Text] [Related]
15. Initiating highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children in Europe and the United States: comparing clinical practice to guidelines and literature evidence. Verweel G; Saavedra-Lozano J; van Rossum AM; Ramilo O; de Groot R Pediatr Infect Dis J; 2006 Nov; 25(11):987-94. PubMed ID: 17072119 [TBL] [Abstract][Full Text] [Related]
16. Gastroduodenal opportunistic infections and dyspepsia in HIV-infected patients in the era of Highly Active Antiretroviral Therapy. Werneck-Silva AL; Prado IB J Gastroenterol Hepatol; 2009 Jan; 24(1):135-9. PubMed ID: 19054257 [TBL] [Abstract][Full Text] [Related]
17. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999 [TBL] [Abstract][Full Text] [Related]
18. Rheumatic manifestations of human immunodeficiency virus infection. Louthrenoo W Curr Opin Rheumatol; 2008 Jan; 20(1):92-9. PubMed ID: 18281864 [TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy. Dai Y; Qiu ZF; Li TS; Han Y; Zuo LY; Xie J; Ma XJ; Liu ZY; Wang AX Chin Med J (Engl); 2006 Oct; 119(20):1677-82. PubMed ID: 17097013 [TBL] [Abstract][Full Text] [Related]
20. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Sheng WH; Kao JH; Chen PJ; Huang LM; Chang SY; Sun HY; Hung CC; Chen MY; Chang SC Clin Infect Dis; 2007 Nov; 45(9):1221-9. PubMed ID: 17918088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]